Background Programmed cell death protein-1 (PD-1) and programmed cell death ligand 1
(PD-L1) inhibitors have remarkable clinical efficacy in the treatment of non-small cell lung …

Programmed death ligand 1 (PD-L1) mediated immune escape play important roles in the
development of cancer. The gene polymorphism of PD-L1, in particular rs4143815 C> G …

Abstract Background Immune checkpoint inhibitors (ICIs) have emerged as promising
therapeutic agents in non-small cell lung cancer (NSCLC). However, the duration for which …

Abstract Anti-programmed death-1 (PD-1) therapy has been extensively used to treat
cancer. Recently, the combination of immunotherapy and anti-angiogenic therapy has …

Nowadays we have novel equipment for lung cancer diagnosis, however; due to lack of
symptoms, lung cancer is still diagnosed at a late stage. Currently we have the following …

PD-L1 expression in pleural effusions (PE) of lung adenocarcinoma (ADC) was compared
with pleural biopsies and the positive expression in PE was correlated with survival time …

Background The programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1)
inhibitors have shown encouraging merits in non-small cell lung cancer (NSCLC) patients …

肺癌是全球最常见肿瘤之一, 其中非小细胞肺癌(NSCLC) 约占肺癌的85%. 目前肺癌的治疗手段
仍然有限, 并且晚期肺癌的预后较差, 严重影响患者的生命健康. 程序性死亡受体1 (PD-1) …

Background Protein tyrosine phosphatase receptor type delta (PTPRD) is a tumor
suppressor that is often inactivated in hepatocellular carcinoma (HCC). However, the …

In both men and women, Lung cancer is the number one cause of cancer-related death. The
disorder is especially difficult to detect, and often develops for elderly patients at an …